A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese

NCT03018665 · Unknown status

Last updated 2026-05-28

This clinical trial is testing whether a combination of a GLP-1 receptor agonist and metformin can help people with newly diagnosed type 2 diabetes who are overweight or obese achieve diabetes remission.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 200 people Planned (estimated).

Who can join Ages 18–65 · all sexes

Timeline Started 2017-02

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT03018665 ↗

Description as written by the study sponsor.

The purpose of this study is to determine the effect of GLP-1 receptor agonist on inducing diabetes remission in newly diagnosed type 2 diabetes who are overweight or obese

Treatments tested

Exenatide Drug

subcutaneous injection，5ug twice a day the first month，10ug twice a day the second and third month
BIAsp30 Drug

subcutaneous injection，fit dosage twice a day in three months
Metformin Drug

oral，0.85g，twice a day in three months

Main thing measured	Rate of Inducing Diabetes Remission
Sponsor	The First Hospital of Jilin University
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03018665 ↗